Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Agree brother! All noise here....it’s a fantasy on how this company is in trouble. Stick with the facts, talk to mgmt and understand they are 1000 x’s smarter than any of these boo birds and bunny’s.
The boo birds will get what they deserve. Leo will guarantee that.
Booya!
Im seeing > 40% PASI 75 within next 6 weeks. I’m seeing then a run to all time highs and a partnership to follow
Let’s chat around July. I’ll be here
Glad we agree for once.
B-absssi results were comparable to Dapto - I’d say 2 gold increase for success
B-OM - currently zero preventative drugs on market - results were outstanding considering the placebo rate of OM was only 60% which is historically about 10-20% lower than normal. Add the historic rates and the trial results just became SUPER!!!
Prurisol TBD in the next 5 weeks. Anything above 25% PASI 75 would be ideal if safety trumps Otezla and it may work faster....
I’d say we have 3 really good chances of two fold increase to market.
Actually: the odds are extremely high IPIX will succeed. Getting through phase 2 is the toughest statistical phase. Our odds just increased two fold to approval. Look it up!
Why not mention those. IPIX pipeline is much more robust and IPIX has never failed a trial. I say IPIX trumps both as it stands now.
“With the positive observation of intra-tumor p53 modulation, the Company will now allocate resources to focus its efforts on completing development of an oral formulation, including performing bridging toxicology work.”
Again, this is fact from company. They are focused on K and Oral formulation.
I just read the Q - - - Here is my observation:
From Nov 6th to January 31st they added 5,561,952 shares. So my reading the Aruda percentage in his filing and then taking the Q showing the Nov 6th was way off.... This makes much more sense on why the share price has been trading in the range of 66-73 for those months. For a stock that does not trade too many shares a day, IF YOU DIVIDE that 5.5 million by the trading days in that range: you would get about 92,700 shares per day!
That is alot and heavy on this stock. We have had great news and Leo has to use those days to use Aspire...it is what it is during this time frame.
Dr. Menon reducing his salary by 50% is great as the Q states they are going to cool it on R&D and Dr. M is the President of Research. That makes sense and I would also pack my pipe with the possibility that K will have a deal inked shortly. As the PR last week stated:
Our time is near!
Kevetrin will be partnered soon.
Brilacidin partnered soon
Prurisol will be sold outright.
Aimo.
Amgen ‘looking hard’ at striking deals using $27bn cash pile
https://www.ft.com/content/02106674-0867-11e8-9650-9c0ad2d7c5b5
Quote:
Amgen, the world’s largest biotech company, has said it is “looking hard” for deals to deploy its $27bn cash pile but warned it is struggling to find targets amid soaring valuations in the life sciences sector.
The note of caution comes as mergers and acquisitions activity in the healthcare sector recorded its strongest start to a year in more than a decade, with almost $32bn of global deals announced since the start of January.
...
“We want to deploy any excess cash and our first priority is to do acquisitions and invest in the business,” said David Meline, Amgen’s chief financial officer, in an interview with the Financial Times.
But he added: “We see all of these deals announced, and we participate pretty actively in considering whether to bid, but we haven’t been able to come up with a business case that would make a return for our shareholders.
“We will keep pushing ourselves and keep looking ourselves, because we have lots of financial flexibility.”
He cautioned it would be difficult “as long as people are willing to pay levels above what we deem we can make a return on”.
Mr Meline was talking before the recent market gyrations, which have sent valuations for biotech groups lower.
Amgen’s stance runs counter to predictions of a deals frenzy from bankers and lawyers, who say they are working on more M&A leads than they have done in years.
The company’s warnings on valuations carry additional weight because it is among the pharmaceutical companies with the most firepower to do big-ticket acquisitions.
Back from a getaway! I see the boo birds have been in control;)
IPIX will seal the deal soon, and all boobirds will disappear. Nothing negative other than minimal dilution for a pre-revenue biotech company. Adding 4 million shares over the Quarter is the only negative.
Brilacidin - Kevetrin - Prurisol
All will be blockbusters imo.
Keep up the 1000% trial success!!!
The good news is they have been testing since late 2016. If they did not see promise they would have cut the cord on Oral K:
Here is from March:
March 3, 2017
Cellceutix Provides Update on Developing p53 Drug Candidate Kevetrin as an Oral Anti-Cancer Agent
Kevetrin
BEVERLY, Mass., March 03, 2017 (GLOBE NEWSWIRE) -- Cellceutix Corporation, (OTCQB:CTIX) (“the Company”), a clinical stage biopharmaceutical company developing innovative therapies with dermatology, oncology, anti-inflammatory, and antibiotic applications, is pleased to update shareholders on continuing efforts to develop the oral dosing of Kevetrin.
Based on positive results from Cellceutix’s Phase 1 trial of Kevetrin in solid tumors conducted at Dana-Farber Cancer Institute and Beth Israel Deaconess Medical Center, the Company is moving forward with a Phase 2 trial of intravenously-administered Kevetrin in patients with late-stage, platinum-resistant ovarian cancer. Cellceutix has decided to pursue an oral formulation for Kevetrin to improve patient convenience and potentially increase therapeutic efficacy given the drug’s short half-life and other pharmacokinetics, as discussed below.
As background, pre-clinical work determined the bioavailability of Kevetrin was 79 percent when given orally in Sprague-Dawley rats. To further establish the efficacy of oral Kevetrin, in vivo mouse studies were carried out in an ascites ovarian tumor model using OVCAR-3 and OV-90 tumor models, both of which possess different mutant p53 genes. Importantly, these pre-clinical results showed that the overall efficacy of Kevetrin was similar across both oral and intraperitoneal routes of drug administration.
Cellceutix has initiated a series of GLP (Good Laboratory Practice) studies to assess the safety of Kevetrin given orally. Considering that Kevetrin is a non-cytotoxic drug, our intent, with FDA permission, is to next proceed with a Phase 1 clinical trial in healthy volunteers using the oral route. These studies are being conducted by approved vendors and include: photosafety testing, pharmacokinetics, in vivo metabolism, metabolic stability, protein binding, and genetic and physiological toxicology reports.
Preliminary data analyses in a pharmacokinetic study in rats revealed a half-life of approximately 1 hour and a clearance of 78ml/min/kg for both oral and intravenous (IV) dosing. Results of an initial photosafety study demonstrated a molar extinction coefficient value of less than 5 L/mol*cm over a range of wavelengths above 290 nm, well below the 1000 L/mol*cm limit stated in ICH guidelines—indicating Kevetrin has no phototoxicity. A preliminary toxicity study showed that at doses up to 500 mg/kg given orally daily for 7 days, Kevetrin was well-tolerated by the rats as indicated by an 11 percent increase in body weight and no abnormal clinical observations. Further, this dose was greater than the doses used in the preclinical efficacy study. Remaining safety studies will be completed in the second half of this year.
In related news: Last week, Cellceutix research partners in Italy shared results with the Company from their ongoing preclinical work evaluating Kevetrin in Acute Myeloid Leukemia (AML), Pancreatic Cancer and human Gliobastoma Multiforme (hGBM). The data will be presented (by them) at scientific conferences, and is consistent with, and further informs, our knowledge of Kevetrin. Also, efficacy data from the 2nd cohort in the Brilacidin-Ulcerative Colitis proof-of-concept study is in the last stage of being compiled by the CRO and, following a final review, will be released.
I keep adding and therefore he can call me a bag holder. I love holding bags for extremely long periods. This one will bare fruits!
“The Company is adhering to a value-building strategy born from discussions with larger pharmaceutical companies interested in Kevetrin, one of the world’s most advanced p53 drug candidates. Securing the right development partner for Kevetrin remains an important objective.”
That should explain it all. IPIX is looking to see who fits the slipper.
Targeting specific genes are getting a lot of attention and the fda loves it! Kevetrin Oral is our shot!
K for sure has a chance to beIPIXs cash cow. I’ll see if I can get an update on the final data on the tox trial. Great news and clarification from dr B!
K has plenty of safety data from the past decade. We just need Oral to work and this is a 10-20 billion a year drug. (Once fully to market to 50% of all cancers)
I......as a long and follow closely, I believe a deal is done. We will see!!!
Go IPIX.
Just checking in. So Menon took a pay cut. Awesome and confident.
They are cutting cost of continuing the phase 2 OC trial because they proved the moa. Now see money is only in Oral? So they said Oral is worth moving forward? They will jump to phase 2 Oral.
I will read the Q tonight.
Deal is done.
Anywhere under a dollar is crazy. Under 5 is phenomenal. Under 10 is a solid investment. Above 10 id first like to see who the partner is and phase 3 results. (Or partners)
I’m one of many here that believe triple digits is a real possibility with this pipeline. Obviously not anytime soon, but down the road....for sure
I heard that all weekend. Open deep in red. Green by early afternoon. It's a lemming game. Follow the heard.
Like a batman signal!?!? If I see that I'm buying more
I would love to see ONE partner for B. And as I’ve said before, I’d love to see part of the agreement to guarantee an open market investment in IPIX of say 10-20 million. Imagine what that would do to rally this share price?!?!
Upfront cash would bolster the books and bring a fair market value as there would be zero need for Aspire. So we now would have non dilutive financing.
Milestone payments give the market cap extra padding in anticipation. And if/when IPIX hits those milestones, another rocket is set off.
Now add that the partner agrees to invest in the open market it would generate extreme buzz and locks down a percentage of the float. A buying frenzy. All the penny flippers can exit and it will be to expensive for all the normal flippers. Bring on Nasdaq and institutional funds.
This could see your number easily.
I know we do have the shelf to offer incentive to some deals but I’d love to see open market deal and lock up the current float.
If the right suitor gets in now, they can make a lot of money off IPIX since we are so undervalued.
Now he is saying he is some attorney or some sort and won’t share his intel will us via links and actual documents. But he will use this forum to discuss what he finds!!! Bahahaaaaaaaaaaaaaa
I’m getting dumber here.
Let’s bring it back to reality: We should see P topline results in Q 1. We have 2 months left. Anytime now.
I really hope this P data is ATLEAST 30% PASI 75. If we can ATLEAST show that, we have a very strong product. Show me less side effects and show me it works in 12 weeks instead of 16.
I personally think we may see some much better numbers but let’s set expectations at 30% PASI 75. ;)
Thanks for the recap on numbers.
I appreciate your warning and opinion, however I will continue to put what pocket change I find into this stock/company and I will sell at my points if they get there. There is absolutely risk here in otcbb bio. But I'm very comfortable with the risk vs reward here.
I think Warren B has many quotes and interviews on long term investing and patience. Also about how the market with all the lemmings and current technology can easily drive the share price of a company to a place that is sooooo off....and those are the companies smart investors will find and invest and keep investing for the long term......because there will in fact be an inflection point or a watershed moment.
I believe iPIX will have that moment in the next 3 months or so.
The "phase 2 blah blah blah" comment makes my point. You have no clue of this science nor wha the company is about. I'm invested here and am a bull on this company for the "phase 2 blah blah blah", I'm in it for the science. I mean....come on: they have not failed one trial. So as a smart investor this is when you jump in heavy! IMO. The company has been beaten down by nefarious articles/authors - lawsuits in which they fought and won! All the while crushing it in 6 human clinical trials and waiting for 2 more.
You can always say whatever you want on a message board - I personally can't stop you. But it's obvious why you post here.
I believe you show concern about preferred shares. So then please do not invest here. I wish you luck finding a better wrap sheet somewhere else. Maybe where there are no p shares. B
Drunken Irishmen? If that is you commenting about IPIX and their Management, you just proved who you are. Leo and Dr Menon got together with one goal. Kill cancer.
They have done nothing but been remarkable in every way. Leo has been the most frugal ceo of a biotech I have ever seen.
In 2012- the company had zero dollars in financing. They had under 100k in cash. They had zero clinical trials. They had only K and P. K was going to start phase 1 in late 2012 when Aspire was brought in under the first agreement. There were just under 100 million shares Outstanding. The share price was .70ish!!!!!!!!!!
Fast forward 6 years!!! OS about 140 million. We captured the B franchise for about 5 million. IPIX has over a million in cash. IPIX has successfully completed: phase 2b absssi, phase 1 Kevetrin, phase 2 poc B-UP, phase 2 b-OM, phase 2 P, crossover phase 1 P:
Pending results; Phase 2b P, and phase 2 Ovarian K
That is 8 human mid stage clinical trials. NOT ONE HAS FAILED!!! The shares have increased by 40 million to pay for 8 trials and pick up a huge franchise of drugs.
I’d say that is very responsible and no where near a drunk Irishman.
By the way. The share price is about the same with all that progress.
I can go into all the designations they have received. ???? But you will still state your opinion on preferred shares. Lol.
After hours deal announcement on a Friday. Now that is what he should worry about
Dec21st last patient follow-up for P phase 2b
Phase 2a last patient visit March 17th
Data release May 24th.
So I think we are looking in March for data.
Risk vs Reward is exactly what one should be looking at. Moving 3 drugs through mid stage trials eliminates extreme risk. Two drugs through phase 2b with the blessing of the fda eliminates MAJOR risk.
Look up the percentages. To get thru phase 2 one has a 30% chance to approval. Once you get thru phase 2b and sit at the start of phase 3 you have a mid 60% chance to approval.
Those odds just doubled to make it.
Evaluate the risk vs reward. I’ll put my money on making it to market on one of 3 drugs. ONE OF THREE!!! Another fact that de-risks this investment.
I think he was talking about B-OM ONLY. The most recent deal only included 1 million upfront for a B-OM drug in Sept. it carried a 100+ million milestone and increasing double digit royalty though. B-OM is much better though, so I expect more, like Bio said, maybe 10-15 million upfront with trials covered and a bigger milestone especially if BTD is granted.
If you are thinking it’s going to be a mega B deal....than the upfront imo would be in the hundred millions and huge-milestones for each indication, and regulatory approval.
A full B deal for the franchise would equate to billions imo by the time they reached regulatory submission.
IBD, B-OM, Dermatology, Antibiotic
That would garner Humira style revenue easily. EASILY. And I’m talking end game - crohns, acne, etc... when the dust settles in 5 years I think all of B could bring in Humira type revs.
It’s not at all. Menon and Leo are the friendliest in the arena. This is how it’s going to go:
Huge deal for B
Major upfront but more importantly major major milestones. They pay Leo back for lending the millions.
They allow the stock to run. And then buy back millions of the 140 when they hit the major milestones.
The pipeline is just too stacked. Cash will be flowing from every which way if they decide to partner all drugs and all indications.
You’ve stated your concern over and over and are not invested - so bye. We won’t miss you and your BS
The PR that runningirl posted is what I was referring of. I’m expecting final results soon.
Looks good so far. For pre clinical to match up with IV is good
:( my heart goes out to you. And people here post garbage to hurt this stock and company while they may have drugs to help people like your sister. I’m so sorry KarinCA
IPIX? To a T
Agree. Someone will sign. But maybe now someone will sign for more :)
Sorry bub. The results were just shown that K modulates P53. Conversation over. The oral preclinical results look good so far.
Final results should be out soon.
Lol. I understand. I’d love to take a payday and just move on, but the value here is potentially just too high for a buyout today. IMO.
The billion dollar indications in unmet need is just too high at IPIX. And they have not even flirted with toxic side effects nor flirted with minimal efficacy. The only negative imo is the K short half-life. But if the can produce Oral K. Problem solved
The good thing for IPIX. The COST to manufacturer Prurisol is pennies. We can offer a lower cost drug and still make tons
The Confidential Disclosure Agreement (CDA) count toward partnering with global and specialty pharmaceutical companies interested in the Company’s first-in-class drug candidates is nearing 20, with additional Agreements in review. Successfully securing partnerships would afford the Company access to immediate and potentially recurring sources of non-dilutive capital, including upfront fees, milestone-based payments and tiered royalties
It’s apparent. Just concentrate on facts. Trial results merit multi billions in revs. Trial results will bring in a partner soon. P results may trump OTEZLA. ALL VERY SOON.
this stock is ready to explode
Ha! I would rather have years of appreciation. But if they can get 20 billion I’d be okay. Otherwise I’d like partnership and for them to continue to kick out new indications. I think 50 billion at some point is not fantasy MC